ATE23716T1 - 5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate. - Google Patents

5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate.

Info

Publication number
ATE23716T1
ATE23716T1 AT83100449T AT83100449T ATE23716T1 AT E23716 T1 ATE23716 T1 AT E23716T1 AT 83100449 T AT83100449 T AT 83100449T AT 83100449 T AT83100449 T AT 83100449T AT E23716 T1 ATE23716 T1 AT E23716T1
Authority
AT
Austria
Prior art keywords
carbon atoms
hydrogen
trinor
prostaglandin
phenylene
Prior art date
Application number
AT83100449T
Other languages
English (en)
Inventor
Kiyotaka Ohno
Hiroshi Nagase
Kazuhisa Matsumoto
Shintaro Nishio
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11630492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE23716(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of ATE23716T1 publication Critical patent/ATE23716T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/09—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis
    • C07C29/12—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of esters of mineral acids
    • C07C29/124—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by hydrolysis of esters of mineral acids of halides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/56—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by isomerisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4015—Esters of acyclic unsaturated acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
AT83100449T 1982-01-20 1983-01-19 5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate. ATE23716T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP57006150A JPS58124778A (ja) 1982-01-20 1982-01-20 ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
EP83100449A EP0084856B2 (de) 1982-01-20 1983-01-19 5,6,7-Trinor-4,8-inter-m-phenylen-prostaglandin I2-Derivate

Publications (1)

Publication Number Publication Date
ATE23716T1 true ATE23716T1 (de) 1986-12-15

Family

ID=11630492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83100449T ATE23716T1 (de) 1982-01-20 1983-01-19 5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate.

Country Status (8)

Country Link
US (1) US4474802A (de)
EP (1) EP0084856B2 (de)
JP (1) JPS58124778A (de)
AT (1) ATE23716T1 (de)
AU (1) AU556348B2 (de)
CA (1) CA1226280A (de)
DE (1) DE3367774D1 (de)
ZA (1) ZA83328B (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1275287C (en) * 1986-01-24 1990-10-16 Kiyotaka Ohno 2,5,6,7-tetranor-4,8-inter-m-phanylene pgi derivatives
US4880939A (en) * 1986-12-11 1989-11-14 Toray Industries 2,5,6,7-tetranor-18,18,19,19-tetradehydro-4,8-inter-m-phenylene PGI2 derivatives
CA2028626C (en) * 1989-02-27 1997-12-09 Kiyotaka Ohno Process for producing 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivatives
EP0389162B1 (de) * 1989-03-14 1993-12-08 Toray Industries, Inc. 2,5,6,7-Tetranor-4,8-inter-m-phenylen-PGI2-Derivate
JP2608135B2 (ja) * 1989-03-31 1997-05-07 科研製薬株式会社 糖尿病性神経障害治療剤
DE4104607A1 (de) * 1991-02-12 1992-08-13 Schering Ag Prostacyclin- und carbacyclinderivate als mittel zur behandlung von fiebrigen erkrankungen
JP3230246B2 (ja) * 1991-04-11 2001-11-19 東レ株式会社 悪性腫瘍転移抑制剤
US5496850A (en) * 1991-04-11 1996-03-05 Toray Industries, Inc. Antimetastasis agent of malignant tumors
US5233059A (en) * 1991-07-25 1993-08-03 Iowa State University Research Foundation, Inc. Synthesis of benzoprostacyclins using palladium catalysis
US5169959A (en) * 1991-09-23 1992-12-08 Iowa State University Research Foundation, Inc. Free radical-catalyzed synthesis of benzoprostacyclins
JP3173008B2 (ja) * 1991-10-25 2001-06-04 東レ株式会社 肝疾患治療剤
JP3102141B2 (ja) * 1992-05-29 2000-10-23 東レ株式会社 養毛育毛剤
CA2152403C (en) * 1992-08-07 2005-06-21 Peter Scholz Use of prostane derivatives of formulae i and ii for the production of a medicament for the treatment of chronic polyarthritis
DE4226615C1 (de) * 1992-08-07 1994-05-19 Schering Ag Verwendung von Prostan-Derivaten zur Behandlung von chronischer Polyarthritis
DE69322496T2 (de) * 1992-09-18 1999-05-06 Toray Industries, Inc., Tokio/Tokyo Sulfonsäure derivat und deren pharmazeutische verwendung
JPH07126161A (ja) * 1993-10-29 1995-05-16 Toray Ind Inc 心不全治療剤
JP3541417B2 (ja) * 1994-02-24 2004-07-14 日産化学工業株式会社 フェニル置換ヒドロキシシクロペンテノン類、ペンタノン類及びフェニル置換プロスタグランジンｉ２類中間体並びにその製造法及び光学分割法
WO1996015793A1 (en) * 1994-11-17 1996-05-30 Toray Industries, Inc. Percutaneously absorbable preparation
CN1127336C (zh) * 1995-02-27 2003-11-12 东丽株式会社 肺性心病治疗剂
CZ168896A3 (en) * 1995-06-27 1997-01-15 Egyt Gyogyszervegyeszeti Gyar Oxaindene derivatives and process for preparing thereof
DE19530884C2 (de) * 1995-08-11 1997-07-31 Schering Ag Verwendung von Prostan-Derivaten sowie deren Kombination mit Antibiotika zur Behandlung von bakteriellen Meningitis
CA2226348A1 (en) 1996-05-07 1997-11-13 Takashi Ikari Ophthalmic preparations
WO1998011899A1 (fr) * 1996-09-17 1998-03-26 Toray Industries, Inc. Agent de potentialisation de la fonction plaquettaire et procede de traitement du dysfonctionnement plaquettaire
KR20000065039A (ko) * 1997-02-27 2000-11-06 히라이 가쯔히꼬 폐순환 개선제
CA2254925A1 (en) * 1997-03-13 1998-09-17 Shigeyasu Annoh Drugs for relieving diabetic vascular lesion
ES2328191T3 (es) * 1997-03-14 2009-11-10 Toray Industries, Inc. Preparacion de derivado de la prostaglandina i de liberacion sostenida.
US6653345B2 (en) 1997-09-16 2003-11-25 Toray Industries, Inc. C-C chemokine synthesis inhibitor
US6919372B1 (en) 1997-12-26 2005-07-19 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical compositions
JP4019481B2 (ja) 1998-01-23 2007-12-12 ソニー株式会社 情報処理装置および方法、情報処理システム、並びに提供媒体
EP1022030A1 (de) * 1998-08-12 2000-07-26 Toray Industries, Inc. Mittel zur regulation der produktion des plasminogen-aktivator-inhibitors 1
WO2000009135A1 (en) * 1998-08-14 2000-02-24 Toray Industries, Inc. Peridermal cell protecting agents
US20030092760A1 (en) * 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
HU227157B1 (en) * 2001-07-30 2010-09-28 Chinoin Gyogyszer Es Vegyeszet Production of beraprost ester by selective oxidation
JP3340732B1 (ja) * 2001-10-05 2002-11-05 日本医薬品工業株式会社 シクロペンタベンゾフラン誘導体の製造方法及びその製造原料となる新規化合物
GB0215757D0 (en) * 2002-07-08 2002-08-14 Cascade Biochem Ltd Benzoprostacyclin intermediates methods for their preparation and products derived therefrom
CA2529351C (en) 2003-05-09 2012-04-17 Toray Industries, Inc. Use of prostaglandin i for enhancing the effect of a renin-angiotensin system inhibitor on a renal disease
JP4157889B2 (ja) * 2003-06-25 2008-10-01 有限会社 循環器研究所 性交機能改善用外用製剤
AU2006267613B2 (en) 2005-07-08 2011-08-11 Toray Industries, Inc. Therapeutic agent and treatment method for ameliorating uremia
JP5424291B2 (ja) * 2006-03-03 2014-02-26 独立行政法人国立循環器病研究センター 骨髄細胞の動員剤および動員方法
CA2669763C (en) * 2006-11-16 2015-02-17 Bayer Schering Pharma Aktiengesellschaft Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection
HUE036071T2 (hu) 2008-08-13 2018-06-28 Actelion Pharmaceuticals Ltd Macitentánt tartalmazó terápiás készítmények
US20120190637A1 (en) 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
KR101701943B1 (ko) 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
WO2012174407A1 (en) 2011-06-16 2012-12-20 Lung LLC Method of producing beraprost
CN103509044A (zh) * 2012-06-21 2014-01-15 上海天伟生物制药有限公司 贝前列素钠中间体及其制备方法
CA2879507A1 (en) 2012-07-19 2014-01-23 Cayman Chemical Company, Inc. Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions
CN103242274B (zh) * 2013-05-22 2014-11-05 孙威 一种贝前列素钠化合物及其制备方法
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
EP3334714A1 (de) 2015-08-12 2018-06-20 United Therapeutics Corporation Verfahren zur herstellung von beraprost
CN106632372B (zh) * 2016-09-26 2019-04-02 上海北卡医药技术有限公司 一种中间体及其制备方法和用途
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
CN107325122B (zh) * 2017-01-06 2020-05-01 常州博海威医药科技股份有限公司 制备贝前列腺素的新中间体及其制备方法
CA3070805A1 (en) 2017-07-27 2019-01-31 Allergan, Inc. Prostacyclin receptor agonists for reduction of body fat
CN109305986B (zh) * 2018-11-13 2021-02-19 济南康和医药科技有限公司 一种贝前列素钠中间体的合成方法
US10577340B1 (en) * 2018-11-26 2020-03-03 Chirogate International Inc. Beraprost-314d crystals and methods for preparation thereof
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合
CN110746450A (zh) * 2019-09-17 2020-02-04 济南康和医药科技有限公司 一种贝前列素钠关键中间体的合成方法
CN112569181B (zh) * 2019-09-27 2023-03-21 中国科学院上海高等研究院 一种快速增溶肾上腺素的方法
EP4103192A4 (de) 2020-02-12 2024-02-21 Cytoagents, Inc. Zusammensetzungen und verfahren zur behandlung von coronavirusinfektionen
TW202317089A (zh) 2021-06-16 2023-05-01 日商東麗股份有限公司 罹患慢性腎臟病的貓的治療方法
TW202317527A (zh) * 2021-06-28 2023-05-01 日商大內新興化學工業股份有限公司 貝前列素或光學活性物之合成中間物及其製造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2734791A1 (de) * 1977-07-29 1979-02-15 Schering Ag Neue prostaglandin-i tief 2 -derivate und verfahren zu ihrer herstellung
JPS5931510B2 (ja) * 1979-09-03 1984-08-02 東レ株式会社 ５，６，７−トリノル−４，８−インタ−ｍ−フエニレンＰＧＩ↓２誘導体
JPS57144276A (en) * 1981-03-03 1982-09-06 Toray Ind Inc 5,6,7-trinor-4,8-inter-m-phenylene pgi2 derivative

Also Published As

Publication number Publication date
US4474802A (en) 1984-10-02
EP0084856B2 (de) 1994-05-04
JPS58124778A (ja) 1983-07-25
ZA83328B (en) 1983-10-26
EP0084856B1 (de) 1986-11-20
AU556348B2 (en) 1986-10-30
EP0084856A1 (de) 1983-08-03
AU1060983A (en) 1983-07-28
DE3367774D1 (de) 1987-01-08
JPH0153672B2 (de) 1989-11-15
CA1226280A (en) 1987-09-01

Similar Documents

Publication Publication Date Title
ATE23716T1 (de) 5,6,7-trinor-4,8-inter-m-phenylen-prostaglandin i2-derivate.
ES527954A1 (es) Un procedimiento para preparar isoxazoles
IL56288A (en) 15-deoxy-16-hydroxy-2-decarboxy-2-hydroxymethylprostaglandin derivatives and their preparation
ES8503667A1 (es) Un procedimiento para la preparacion de nuevos derivados de 2-oxo-imidazolina.
ES8401961A1 (es) Procedimiento para la preparacion de nuevas n-(4-indolil-piperidino-alcohil-bencimidazolonas sustituidas.
ES8304567A1 (es) "un procedimiento para preparar nuevos derivados de la n-dihidrotiazolil-3-quinolein-carboxamida".
ES8800145A1 (es) Un procedimiento para preparar un derivado de semicarbazida
DE3477488D1 (en) Polymethoxybenzyl piperazine derivatives, processes for their preparation and pharmaceutical compositions containing said derivatives
MX9206127A (es) Compuestos de acetileno
JPS5750989A (en) Imidazole compound
IL77124A (en) 5-alkyl-1-phenyl-2-piperazinoalkylpyrazolin-3-one compoundds,their preparation and pharmaceutical compositions containing them
AU550340B2 (en) Dibenzazepine derivatives
DE3266845D1 (en) Hydrocortisone derivatives, their preparation and their utilization
AU562253B2 (en) Thiazolothienoazepine or pyridiue derivatives
CA1273946C (en) ANTICONVULSANT GAMMA-THIOBUTYROLACTONE DERIVATIVES
ES8200648A2 (es) Procedimiento de preparacion de compuestos opacificantes para radiografia y similares
AU8672582A (en) Benzodioxane substituted imidazolines
ES8401008A1 (es) Procedimiento para la preparacion de derivados de carbaciclina.
DE3264556D1 (en) Sulfimines, their salts and their preparation, and pharmaceutical compositions containing them
JPS52100470A (en) Synthesis of hydantoin derivatives
DE3363575D1 (en) Furyloxazolylacetic acid derivatives, process for preparing same and pharmaceutical compositions containing same
ES8103742A2 (es) Un procedimiento de preparacion de nuevos derivados de 1,3-benzodioxina
IL70103A0 (en) Semicarbazides,their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time